Member Info for Rocky500

https://www.thisismoney.co.uk/money/diyinvesting/article-9664613/Dont-lose-shirt-Crypto-Casino-Bitcoin-crashes-half.html

That comment doesn't make a lot of sense considering the 8m mcap valuation at £1 per share previously equates to 11.5p now or thereabouts. Therefore its worth more than before.

What's not factored in previously is stock profile as I suspect the number of shares traded was close to 0 daily. That's where TB has done his job raising the profile and enabling the raise and the subscribers to get their money back.

I suspect with the new business model and direction there is certainly growth potential and with the share enjoying a higher profile no doubt will enable that potential to translate into a higher sp.

Comparisons to previous sp performance therefore is a bit pointless.

Again you have concurred with my point. This has the potential calibre of being of interest to the likes of Fuji but that takes time. It may ultimately appear in airports in a few years time alongside the drugs and explosive test machine. What it isn't is the high volume celebrity solution that has made some people very rich.

It may well be the government would like the test but I do get a sense of others nipping at the heels. The quiet from the company suggests theres no razmataz surrounding the product to get the tie ups with the likes of BA. I've no doubt it will make it to market, but as a 'serious piece of kit' and not one that will become a 'household name'.

The government has been quite two faced so far - wanting the best but buying from China...

You have sort of tuned into my point - whilst this is a better test and will stand the test of time it may be that it no longer offers the quick solution commercially if there are others that can on the face of it beat the time and satisfy the lesser requirements demanded by the commercial sector.

The Paraytec test will undoubtedly do well in the medical device space but the volume market may be too competitive ultimately. We will see.

Read the article in Sky News about this...suffice to say if it works as they think it does then it will be hard to wrestle it away and replace with a 2min test that isn't currently endorsed by the airline industry....it may be the market size for the BRH test is being reduced to more medical establishments and less commercial. It still has a long life ahead of it but perhaps in a smaller arena....we will see but this looks like it could genuine competition.

I would suggest there's quite a few errors with this statement as it's not possible to speculate the destination of any of TB's cash although the sale of BRH the day before the placing here suggests the two are connected.

The Aptamer group has no control over any thing at BRH as far as I am aware as they didn't pursue a relationship last year and they got the aptamer refined elsewhere. Paraytec own all front end IP to to with the technology and are able to proceed without any links to others from my understanding. Not saying its a guaranteed route to success but I know TB didn't want complications or reliance on others when developing the technology as that potentially devalues it.

If you look at the TR1's that were issued just after the placing you will see around 10m of the 40m shares have been squirreled away.

Its good to take a breather as the metrics were all pointing to overbought. Thus far you cant buy back in for any less than you could sell so its just resting for a bit.

Long way to go yet.

The share cant support 20m or large part thereof being dumped on the market yet. It's a case of building the following at the moment whilst implementing the turnaround plan. When they start to deliver real results you will have a much higher sp and a wider audience in which to sell into.

Chances are there is some profit taking and possibly some of the placing shares being offloaded that weren't take up ny TB or other major holders who took part in the placing.

TB is not a serial diluter so unless he sticks his hand in his pocket to balance up his 29.9% in any further placing he feels the £3.5m is enough to get the company back on its feet. The redundancy liabilities are a significant one time cost and therefore a hurdle to the greener pasture on the other side (assuming it's not a draught ridden dust bowl obviously).
Once those costs are out of the way the company, which is revenue creative will benefit from the reduced overheads to the extent it becomes sufficiently cash generative to be self supportive.

Chances are a chunk of the £3.5m placing will go on exit costs and the rest of the restructuring. Without the cash they would unlikely have been able to cover these cost making the company technically insolvent. With this injection of cash they can shrink the workforce and with it ongoing overheads so to restore decent profitability. So long as they are able to emerge leaner and keener for the work that's out there then bingo they are off to the races.

Agreed its best not to get too greedy with your exit point to try and preempt TB. But there's work still to be done here so it won't be for a while although if it goes mad then he too may take some off the table. Considering the company owns its property the valuation currently is technically too low still although consideration has been given to recent events etc. If TB is waving his wand then good chance the ship will be put back on course.

I've a client in the south west who is a specialist casting company and they've seen a real renaissance over the past few years so there is definitely demand for the services Chamberlin offer; they will likely need to be creative to exploit the opportunities out there.

The tech is now proven. The addition of further improvements only goes to show the versatility of the approach and the potential offshoot products and services this development can merge into. It has years and years of development potential and a whole range of products that can be spun of this IP so theres a good chance this concept will replace a whole range of diagnostic methods over the coming years and months. That makes the IP worth millions...and many of those at that.

The ct value of BRH means its results are 4 to 5 times better than AVCT in terms of S&S results. There is no comparison really here as BRH have set their bar so much higher than everyone else. This will make the IP worth so much more than the LFT as it can be migrated over to so many other uses.

At a ct value of 37 the results are extraordinary and there is still room for improvement. This tech is the future of diagnostics as it's so adaptable.

RNS Friday 29th Jan....its amazing how little some people read even though they invest!

The RNS in January did say they would report back by end of Feb and it was in fact 1st March so it's been done before but still delivered on time (sort of)...

Event.

The punters would need to have their heads doused in fluorescent liquid...which given the ecent shouldn't be a problem...